Antithrombotic Therapy After Coronary Artery Bypass Grafting Combined With Coronary Endarterectomy

Phase

Condition

Blood Clots

Treatment

Warfarin

CE+CABG

DAPT

Clinical Study ID

NCT05782270

2022-GSP-QN-11

Ages > 18
All Genders

Study Summary

Coronary endarterectomy (CE) combined with coronary artery bypass grafting (CABG) can be the final option for achieving complete revascularization in diffuse coronary artery disease patients. Since the exposure of subendothelial tissue to the blood flow after CE, the coagulation cascade can be activated, resulting in the increased risk of graft failure. Therefore, anticoagulation with warfarin in this group of patients might be beneficial. However, evidence is limited. This study aims to compare the clinical outcomes between dual antiplatelet therapy with or without warfarin after CE+CABG.

Eligibility Criteria

Inclusion

Inclusion Criteria:

Adult patients with diffuse coronary artery disease undergoing CE+CABG during thestudy period.
No contraindications for both dual antiplatelet therapy and anticoagulation therapywith warfarin.
Must be able to swallow tablets after the surgery.

Exclusion

Exclusion Criteria:

Patients with high bleeding risk (HAS-BLED ≥ 3);
Patients undergoing concomitant aortic valve or mitral valve surgery, or undergoingcardiac surgery for the second time;
Emergency surgery;
Serum creatinine >130μmol/L, or significant liver dysfunction (elevated ALT and/orAST);
History of digestive or urinary tract bleeding, active gastric bleeding caused bygastric ulcer, or postoperative new-onset gastric bleeding;
History of hemorrhagic stroke, or platelet dysfunction;
Allergic or with contraindication to any of aspirin, clopidogrel or warfarin;
Participated in other clinical trial for drug or device within 30 days;
Pregnant or planning to be pregnant.

Study Design